{"id":"pegylated-interferon-alpha-2","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"30-70","effect":"Headache"},{"rate":"25-60","effect":"Myalgia"},{"rate":"20-40","effect":"Depression/mood changes"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-25","effect":"Neutropenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alpha-2 is a cytokine that stimulates natural killer cells, macrophages, and T lymphocytes to mount antiviral and antitumor responses. Pegylation (attachment of polyethylene glycol) extends the drug's half-life and reduces immunogenicity, allowing for less frequent dosing while maintaining therapeutic efficacy. This modified form is used primarily in chronic viral infections and certain malignancies.","oneSentence":"Pegylated interferon alpha-2 activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:16.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)"}]},"trialDetails":[{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT05970289","phase":"PHASE2","title":"Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2023-08-22","conditions":"Chronic Hepatitis B Virus Infection","enrollment":86},{"nctId":"NCT06650852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)","status":"RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-10-31","conditions":"Chronic Hepatitis B Virus (HBV) Infection","enrollment":250},{"nctId":"NCT06491563","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-08-06","conditions":"For Treatment of Chronic Hepatitis B Virus Infection","enrollment":150},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT04676724","phase":"PHASE2","title":"Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-28","conditions":"Hepatitis B","enrollment":108},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT05729139","phase":"PHASE1","title":"Cemiplimab/Peg-Interferon-α in Advanced CSCC","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2023-07","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21},{"nctId":"NCT05451420","phase":"NA","title":"Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2017-12-01","conditions":"Chronic Hepatitis B","enrollment":33},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT03588715","phase":"PHASE1","title":"Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)","status":"UNKNOWN","sponsor":"Luis Montaner","startDate":"2020-06-18","conditions":"HIV, HIV/AIDS, HIV-1 Infection","enrollment":15},{"nctId":"NCT00525031","phase":"PHASE2","title":"Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08","conditions":"Melanoma","enrollment":55},{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT01294618","phase":"PHASE2","title":"Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-03","conditions":"Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT02726789","phase":"PHASE2","title":"Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2012-10","conditions":"Hepatitis B, Chronic","enrollment":5},{"nctId":"NCT01295515","phase":"PHASE1, PHASE2","title":"Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-11","conditions":"HIV Infection","enrollment":7},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02452814","phase":"","title":"Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-07","conditions":"HCV","enrollment":8},{"nctId":"NCT01193699","phase":"PHASE1, PHASE2","title":"Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2010-08","conditions":"Polycythemia Vera","enrollment":24},{"nctId":"NCT02508090","phase":"","title":"Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-02","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01725204","phase":"PHASE2","title":"Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2012-09","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":40},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00204529","phase":"PHASE3","title":"Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-10","conditions":"Melanoma","enrollment":901},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00467077","phase":"PHASE2","title":"Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"California Cancer Consortium","startDate":"2004-09","conditions":"Kidney Cancer","enrollment":21},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00209209","phase":"PHASE3","title":"Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-01-14","conditions":"Lymphoma, Mantle-Cell","enrollment":570},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT02829775","phase":"PHASE2, PHASE3","title":"A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma","enrollment":9},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT01358864","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"Hepatitis C, Chronic","enrollment":678},{"nctId":"NCT01399619","phase":"PHASE3","title":"Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":310},{"nctId":"NCT01531166","phase":"","title":"A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Chronic Hepatitis B","enrollment":500},{"nctId":"NCT01258101","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":395},{"nctId":"NCT00747539","phase":"","title":"Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-07","conditions":"HIV, Hepatitis C, Infections","enrollment":330},{"nctId":"NCT02661477","phase":"PHASE2","title":"Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2016-05","conditions":"Rhinovirus Infection","enrollment":20},{"nctId":"NCT00680173","phase":"PHASE4","title":"Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT02377856","phase":"PHASE4","title":"Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2007-06","conditions":"Acute Hepatitis C","enrollment":20},{"nctId":"NCT02690103","phase":"PHASE2","title":"Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-07","conditions":"Hepatitis C, Chronic","enrollment":37},{"nctId":"NCT01471574","phase":"PHASE3","title":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C, Genotype 1","enrollment":549},{"nctId":"NCT01637532","phase":"PHASE1, PHASE2","title":"Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-02","conditions":"Recurrent Ovarian Cancer","enrollment":21},{"nctId":"NCT02646189","phase":"PHASE1, PHASE2","title":"Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":12},{"nctId":"NCT00774397","phase":"PHASE2","title":"Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":719},{"nctId":"NCT00241241","phase":"PHASE2","title":"Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera","status":"COMPLETED","sponsor":"PV-Nord","startDate":"2004-09","conditions":"Polycythemia Vera","enrollment":40},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT01297270","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Hepatitis C","enrollment":658},{"nctId":"NCT00984620","phase":"PHASE2","title":"Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-09","conditions":"Hepatitis C","enrollment":160},{"nctId":"NCT00630084","phase":"PHASE4","title":"Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-08","conditions":"Chronic Hepatitis C, Neoplasms","enrollment":120},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT00433069","phase":"PHASE2","title":"Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":5},{"nctId":"NCT00594880","phase":"PHASE2","title":"Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2008-01","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT01529073","phase":"PHASE2","title":"Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection","status":"UNKNOWN","sponsor":"Juan Macías","startDate":"2012-02","conditions":"HCV Coinfection, HIV Infection","enrollment":45},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT00540345","phase":"PHASE4","title":"Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-10","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT00979706","phase":"PHASE4","title":"Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2005-03","conditions":"HIV","enrollment":22},{"nctId":"NCT01872936","phase":"PHASE2","title":"Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection","status":"UNKNOWN","sponsor":"Santaris Pharma A/S","startDate":"2013-06","conditions":"Hepatitis C, Chronic","enrollment":20},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00535847","phase":"PHASE2","title":"A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-10","conditions":"Hepatitis C","enrollment":117},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT02160080","phase":"PHASE3","title":"Boceprevir Treatment in Liver Pre-transplant HCV Patients","status":"UNKNOWN","sponsor":"Hu Tsung-Hui","startDate":"2014-01","conditions":"Late Complication From Liver Transplant","enrollment":20},{"nctId":"NCT00701298","phase":"PHASE1","title":"Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":30},{"nctId":"NCT01639885","phase":"PHASE1, PHASE2","title":"Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-08","conditions":"Recurrent Ovarian Cancer","enrollment":15},{"nctId":"NCT01727934","phase":"PHASE2","title":"Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Santaris Pharma A/S","startDate":"2012-11","conditions":"Hepatitis C","enrollment":10},{"nctId":"NCT02027493","phase":"NA","title":"Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":46},{"nctId":"NCT00580801","phase":"PHASE2","title":"An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-01","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT00006039","phase":"PHASE2","title":"Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-12","conditions":"Lymphoma, Small Intestine Cancer","enrollment":""},{"nctId":"NCT01172392","phase":"PHASE3","title":"A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-01","conditions":"Chronic Hepatitis B, AgHbs Negativation","enrollment":185},{"nctId":"NCT00136318","phase":"PHASE3","title":"Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-01","conditions":"Depression","enrollment":208},{"nctId":"NCT01374308","phase":"PHASE3","title":"NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients","status":"UNKNOWN","sponsor":"Clinical Research Organization, Dhaka, Bangladesh","startDate":"2011-06","conditions":"Chronic Hepatitis B","enrollment":160},{"nctId":"NCT00227656","phase":"PHASE2","title":"Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pegylated interferon alpha 2","genericName":"Pegylated interferon alpha 2","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2 activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}